Close Menu

MD Anderson

An MD Anderson-led team also used longitudinal single-cell sequencing to show how clonal architecture changed in response to AML treatment.

The DrBioRight system goes beyond NLP to produce "natural-language understanding" through AI as it creates automated dialog with researchers to speed up data analysis.

In PNAS this week: possible treatment targets in KRAS-mutated lung cancer, transcriptional analysis of mouse models lacking a p53 inhibitor, and more.

TargetCancer is activating two enrollment sites and setting up a remote consenting process so patients with rare cancers can be seen at local community hospitals.

Both PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in upper respiratory specimens and may only be performed by their developers.

The collaboration will allow oncologists a streamlined view of the treatments and trials available to patients based on their genomic profile.

Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.

Integrated analyses uncovered recurrent changes in renal medullary carcinoma, including potential treatment vulnerabilities stemming from DNA replication stress.

A single-cell "atlas" of pathologically normal breast tissue was presented by an MD Anderson Cancer Center representative at the AACR's online annual meeting this week.

Tumors from patients who underwent full surgical resection had distinct molecular profiles from those treated with neoadjuvant chemotherapy.

Pages

According to CNBC, Pfizer has announced that its SARS-CoV-2 vaccine data won't be ready this week.

A number of United Nations agencies push for scientific findings to be made accessible through open science.

Paris-Saclay University garners international regard following a decade-long effort to establish the new research university, Nature News reports.

In Nucleic Acids Research this week: database to house IndiGen sequencing data, database of SARS-CoV-2 docking scores, and more.